...
首页> 外文期刊>The American Journal of Psychiatry >Four-Year Longitudinal Course of Children and Adolescents With Bipolar Spectrum Disorders: The Course and Outcome of Bipolar Youth (COBY) Study
【24h】

Four-Year Longitudinal Course of Children and Adolescents With Bipolar Spectrum Disorders: The Course and Outcome of Bipolar Youth (COBY) Study

机译:儿童和青少年双极性频谱障碍的四年纵向课程:双极性青年(COBY)研究的过程和结果

获取原文
获取原文并翻译 | 示例
           

摘要

The authors sought to assess the longitudinal course of youths with bipolar spectrum disorders over a 4-year period. At total of 413 youths (ages 7-17 years) with bipolar I disorder (N=244), bipolar II disorder (N=28), and bipolar disorder not otherwise specified (N = 141) were enrolled in the study. Symptoms were ascertained retrospectively on average every 9.4 months for 4 years using the Longitudinal Interval Follow-Up Evaluation. Rates and time to recovery and recurrence and week-by-week symptomatic status were analyzed. Approximately 2.5 years after onset of their index episode, 81.5% of the participants had fully recovered, but 1.5 years later 62.5% had a syndromal recurrence, particularly depression. One-third of the participants had one syndromal recurrence, and 30% had two or more. The polarity of the index episode predicted that of subsequent episodes. Participants were symptomatic during 60% of the follow-up period, particularly with subsyndromal symptoms of depression and mixed polarity, with numerous changes in mood polarity. Manic symptomatology, especially syndromal, was less frequent, and bipolar II was mainly manifested by depressive symptoms. Overall, 40% of the participants had syndromal or subsyndromal symptoms during 75% of the follow-up period, and 1 6% of the participants experienced psychotic symptoms during 17% the follow-up period. Twenty-five percent of youths with bipolar II converted to bipolar I, and 38% of those with bipolar disorder not otherwise specified converted to bipolar I or II. Early onset, diagnosis of bipolar disorder not otherwise specified, long illness duration, low socioeconomic status, and family history of mood disorders were associated with poorer outcomes. Bipolar spectrum disorders in youths are characterized by episodic illness with subsyndromal and, less frequently, syndromal episodes with mainly depressive and mixed symptoms and rapid mood changes.
机译:作者试图评估四年期间患有双相谱障碍的青年的纵向病程。本研究共纳入413名I型双相情感障碍(N = 244),II型双相情感障碍(N = 28)和其他未指明的双相情感障碍(N = 141)的青年(7-17岁)。使用纵向间隔随访评估,平均4年平均每9.4个月回顾一次症状。分析了恢复和复发的速率和时间以及每周的症状状态。指数发作开始约2.5年后,81.5%的参与者已完全康复,但1.5年后62.5%的患者出现了综合征复发,尤其是抑郁症。三分之一的参与者患有一种综合征复发,而30%的参与者具有两种或两种以上复发。索引情节的极性可预测后续情节的极性。在随访的60%期间,参与者有症状,特别是患有亚症状的抑郁症和混合极性,并在情绪极性上有许多变化。躁狂症状,尤其是症状性症状少见,而躁郁症II主要表现为抑郁症状。总体而言,有40%的参与者在随访期的75%内有症状或亚综合征的症状,有6%的参与者在随访期的17%内有精神病的症状。 25%患有双相情感障碍II的年轻人转换为双相I,并且38%的未患双相情感障碍的年轻人转化为双相I或II。早期发作,双相情感障碍的诊断(未另作说明),病程长,社会经济地位低以及情绪障碍的家族史与不良预后相关。年轻人的双相谱障碍的特征是发作性疾病,患有亚综合征,少见的是综合征发作,主要表现为抑郁和混合症状以及情绪快速变化。

著录项

  • 来源
    《The American Journal of Psychiatry》 |2009年第7期|p.795-804|共10页
  • 作者单位

    Boris Birmaher, M.D.David Axelson, M.D.Benjamin Goldstein, M.D.Michael Straber, Ph.D.Mary Kay Gill, M.S.N.Jeffrey Hunt, M.D.Patricia Houck, M.S.H.Wonho Ha, Ph.D.Satish Iyengar, Ph.D.Eunice Kim, Ph.D.Shirley Yen, Ph.D.Heather Hower, M. S.W.Christianne Esposito-Smythers, Ph.D.Tina Goldstein, Ph.D.Neal Ryan, M.D.Martin Keller, M.D.Received Oct. 23, 2008, revisions received Dec. 21, 2008, and Feb. 10, 2009, accepted Feb. 17, 2009 (doi: 10.1 176/appi.ajp.2009.08101 569). From the Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Department of Psychiatry and Human Behavior, Warren Alpert Medical School, Brown University, Providence, R.I., Department of Statistics, University of Pittsburgh. Address correspondence and reprint requests to Dr. Birmaher, Western Psychiatric Institute and Clinic, 3811 O'Hara St., Pittsburgh, PA 15213, birmaherb@upmc.edu (e-mail).Dr. Birmaher has participated in forums sponsored by Forest, Shire, Jazz Pharmaceuticals, Solvay, and Abcomm and receives royalties from Random House and Lippincott Williams & Wilkins. Dr. Keller has received research support from, served as consultant to, or served on speakers bureaus or advisory boards for Abbott, Bristol-Myers Squibb, CENEREX, Cephalon, Cypress Bioscience, Cyberonics, Forest, Janssen, JDS, Medtronic, Neuronetics, Novartis, Organon, Pfizer, Roche, Solvay, and Wyeth. All other authors report no competing interests.Supported by NIMH grants MH59929 (to Dr. Birmaher), MH59977 (to Dr. Straber), and MH59691 (to Dr. Keller).The authors thank Carol Kostek for her assistance with manuscript preparation and Shelli Avenevoli, Ph.D., at NIMH, for her support and guidance.,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号